Incidence and Survival of Gastro-Entero-Pancreatic Neuroendocrine Neoplasms in the Contemporary Era

What are the contemporary incidence, overall survival, and cancer-specific survival of gastro-entero-pancreatic neuroendocrine neoplasms (GEP-NENs)?In this cohort study conducted in Ontario, Canada, from 2000 to 2023, 12 877 individuals were diagnosed with GEP-NENs. The incidence of GEP-NENs increased from 1.83 to 7.46 per 100 000, predominantly due to nonmetastatic disease, with 10-year overall survival of 63.3% and 10-year cancer-specific survival of 76.4%.These findings suggest that the rising burden of GEP-NENs largely reflects increased detection of early-stage disease, and although long-term survival is generally favorable, substantial heterogeneity persists, underscoring the need for tailored patient counselling, survivorship planning, and health-system resource allocation.

Corresponding Author: Julie Hallet, MD, MSc, Susan Leslie Clinic for Neuroendocrine Tumors, Odette Cancer Centre, Sunnybrook Health Sciences Centre, 2075 Bayview Ave, Toronto, ON M4N 3M5, Canada (Julie.hallet@sunnybrook.ca).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.